-
Mashup Score: 22Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS - PubMed - 1 month(s) ago
Early intervention of smoldering multiple myeloma (SMM) may delay progression to multiple myeloma. Here, we present the final analysis of the phase 2 CENTAURUS study (NCT02316106). In total, 123 patients with intermediate/high-risk SMM were randomized to intravenous daratumumab 16 mg/kg following a …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 12Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A Roadmap - PubMed - 1 month(s) ago
Improvements in multiple myeloma (MM) treatments have extended patient survival to a decade or more. Treatment response rates >90% have introduced new challenges for drug development, including a need for early endpoints with greater sensitivity. The FDA, based on data from two academic research …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17Riverside - 3 month(s) ago
Create your own studio-quality content.
Source: riverside.fmCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 52024 ESMO East — Total Health - 4 month(s) ago
Total Health’s 2024 ESMO Review will be a condensed review of the global meeting and will give healthcare providers the opportunity to learn about the latest advances in oncology education and translate science into better patient care.
Source: www.totalhealthoncology.comCategories: General Medicine News, Hem/OncsTweet-
ESMO EAST 2024 USA: European Society for Medical Oncology & Total Health Conferencing partner to expand access to the latest developments in cancer This FREE conference will cover highlights from ESMO Congress 2024 Conrad Ft Lauderdale Beach, Oct 26-27 https://t.co/Lcwox41eaY https://t.co/tLbIA46ZSD
-
-
Mashup Score: 29Assistant Professor of Clinical - Medicine, Myeloma - 4 month(s) ago
Current Employees: If you are a current Staff, Faculty or Temporary employee at the University of Miami, please click here to log in to Workday to use the internal application process. To learn how to apply for a faculty or staff position using the Career worklet, please review this tip sheet. Faculty Position Assistant Professor Department of Medicine Job Summary: This faculty position will have research responsibilities within the Department of Medicine, Division of Myeloma, and the Sylvester Comprehensive Cancer Center. The individual in this position will focus on research efforts conducting and developing genome sequencing of multiple myeloma (MM) and other plasma dyscrasias. He/She will have attending physician duties in the Division of Myeloma, with focus on the care and treatment of patients with plasma cell disorders and will focus on the care and treatment of patients with hematologic malignancies. This includes outpatient care, as well as inpatient attending responsibilities
Source: umiami.wd1.myworkdayjobs.comCategories: General Medicine News, Hem/OncsTweet-
We are EXPANDING our innovative &highly successful myeloma program in beautiful #Miami! We are looking to recruit FULL-TIME FACULTY MYELOMA PHYSICIAN at Division of Myeloma & Myeloma Research Institute, @univmiami APPLY HERE: https://t.co/LDw63gD2UJ #mmsm @theMMRF @IMFmyeloma https://t.co/Fdpxa97x7Z
-
-
Mashup Score: 16BostonGene and Sylvester Comprehensive Cancer Center at the University of Miami Collaborate to Advance Care for Cancer Patients | BostonGene - 6 month(s) ago
Our website uses essential, functional and analytical cookies to improve and personalize your browsing exp erience and collect anonymous data for analytics purposes. For more information on how we use cookies and for contact information to address further questions or concerns, please see our Privacy Policy. By consenting, you are agreeing to the use of cookies as outlined in the Privacy Policy. This website uses cookies to improve your experience while you navigate through the website. Necessary Cookies
Source: bostongene.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 31Highlights in Multiple Myeloma From ASCO and EHA 2024 - 7 month(s) ago
Are you prepared to apply the latest clinical trial evidence in your practice? Our experts review the data.
Source: www.medscape.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 27How Quadruplet Therapy Is Changing the Myeloma Treatment Landscape - 7 month(s) ago
Ola Landgren, MD, PhD, of the Sylvester Comprehensive Cancer Center, joins Blood Cancers Today to discuss quadruplet therapy in newly diagnosed multiple myel…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 45Dr. C. Ola Landgren on Quadruple Therapies and the Future of Multiple Myeloma Treatment - InventUM - 8 month(s) ago
Dr. C. Ola Landgren, will present an overview of new multiple myeloma studies at the annual meeting of ASCO.
Source: news.med.miami.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma - 8 month(s) ago
Key Points. Hyperdiploid, historically considered an initiating event in multiple myeloma, can be preceded by deletions involving driver genes.Deletions wi
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
Efficacy & Safety of Daratumumab in Intermediate/High-risk Smoldering Myeloma: Final Analysis of CENTAURUS Study. With 7 yrs median followup it highlights the tolerability of Daratumumab & supports ongoing trials #mmsm @IMFmyeloma @theMMRF https://t.co/kaodJwhZs2